Classical antagonistic antibodies (Abs) targeting PD-1, such as pembrolizumab and
nivolumab, act through blockade of the PD-1–PDL-1 interaction. Here, we have identified …

Classical antagonistic antibodies (Abs) targeting PD-1, such as pembrolizumab and
nivolumab, act through blockade of the PD-1–PDL-1 interaction. Here, we have identified …

e15118 Background: Monoclonal antibodies (Abs) that act through PD-1 blockade have had
significant clinical success in cancer immunotherapeutic agents with current Abs relying on …

Background Inhibition of T cell activation and effector function via engagement of the co-
inhibitory receptor PD-1 is a critical mechanism enabling tumors to evade host immunity …

Antibodies that block the interaction between PD-1 expressing T-cells and cancer cells
expressing PD-L1 play a central role in contemporary immunotherapy regimes [[1],[2],[3]] …

Monoclonal antibodies targeting the programmed cell death protein 1 (PD-1) remain the
most prevalent cancer immunotherapy both as a monotherapy and in combination with …

3072 Background: Monoclonal antibodies (mAbs) that act through PD-1 blockade have had
significant clinical success as cancer immunotherapeutic agents particularly in melanoma …

Monoclonal antibodies (mAbs) targeted to the programmed cell death protein 1 (PD-1)
remain the most prevalent cancer immunotherapy both as a monotherapy and in …

Structural immunology, focusing on structures of host immune related molecules, enables
the immunologists to see what the molecules look like, and more importantly, how they work …

Abstract Pembrolizumab (MK-3475), a humanized monoclonal IgG4 antibody against
programmed death receptor 1 (PD-1), has shown activity in multiple types of cancer …